Is having more preapproval data the best way to assure drug safety?

DSpace/Manakin Repository

Is having more preapproval data the best way to assure drug safety?

Citable link to this page

 

 
Title: Is having more preapproval data the best way to assure drug safety?
Author: Garber, Alan M
Citation: Garber, Alan M. 2008. Is having more preapproval data the best way to assure drug safety? Health Affairs 27, 5:371-373
Access Status: Full text of the requested work is not available in DASH at this time (“dark deposit”). For more information on dark deposits, see our FAQ.
Full Text & Related Files:
Abstract: An intensified focus on drug safety often leads to demands for more data collection prior to drug approval. Other approaches can be used, such as enhanced postmarketing surveillance. Many drug benefits and adverse effects are unlikely to become apparent before wide distribution among diverse patients. The best balance of pre- and postapproval data collection may vary by drug. The consequences of alternative strategies are complex and not always immediately apparent, so formal modeling offers the best approach to determine which strategy is optimal in each case.
Published Version: doi:10.1377/hlthaff.27.5.w371
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:11577991
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters